Literature DB >> 6802650

Clinical and biological effects of low doses of (3 amino-1 hydroxypropylidene)-1,1-bisphosphonate (APD) in Paget's disease of bone.

G Heynen, P Delwaide, O L Bijvoet, P Franchimont.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6802650     DOI: 10.1111/j.1365-2362.1982.tb00936.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


× No keyword cloud information.
  9 in total

1.  Post-partum hypercalcemia in hereditary hyperphosphatasia (juvenile Paget's disease).

Authors:  N Chosich; F Long; R Wong; D J Topliss; J R Stockigt
Journal:  J Endocrinol Invest       Date:  1991 Jul-Aug       Impact factor: 4.256

2.  Comparison between visual assessment and quantitative measurement of radioactivity on the bone scintigram in Paget's disease of bone.

Authors:  C J Vellenga; E K Pauwels; O L Bijvoet
Journal:  Eur J Nucl Med       Date:  1984

3.  Clinical experience with the use of two diphosphonates in the treatment of Paget's disease.

Authors:  P Dewis; B K Prasad; D C Anderson; S Willets
Journal:  Ann Rheum Dis       Date:  1985-01       Impact factor: 19.103

Review 4.  Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.

Authors:  A Fitton; D McTavish
Journal:  Drugs       Date:  1991-02       Impact factor: 9.546

5.  Paget's disease of bone: five regimens of pamidronate treatment.

Authors:  T Pepersack; R Karmali; C Gillet; D François; M Fuss
Journal:  Clin Rheumatol       Date:  1994-03       Impact factor: 2.980

Review 6.  Bisphosphonates and the treatment of bone disease in the elderly.

Authors:  A Johansen; M Stone; F Rawlinson
Journal:  Drugs Aging       Date:  1996-02       Impact factor: 3.923

Review 7.  Drugs used in the treatment of metabolic bone disease. Clinical pharmacology and therapeutic use.

Authors:  S Patel; A R Lyons; D J Hosking
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

8.  Low dose intravenous 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD) for the treatment of Paget's disease of bone.

Authors:  J A Cantrill; H M Buckler; D C Anderson
Journal:  Ann Rheum Dis       Date:  1986-12       Impact factor: 19.103

Review 9.  Management of osteoporosis and Paget's disease. An appraisal of the risks and benefits of drug treatment.

Authors:  C Gennari; R Nuti; D Agnusdei; A Camporeale; G Martini
Journal:  Drug Saf       Date:  1994-09       Impact factor: 5.606

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.